title: A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia.
abstract: The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy-four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in ≥60% of cells, with a median TTFT of 49 months (CI95%, 39-58) vs 30 months (CI95%, 22-38) (P = 0.001); and a median OS of 159 months (CI95%, 119-182), vs 96 months (CI95%, 58-134) (P = 0.015). Other factors associated with a shorter TTFT were: Binet stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, 11q-, high β2 microglobulin, and high LDH. In the multivariate analysis, clinical stage, +12 in ≥60% of cells, high lymphocyte count, B symptoms, and 11q- in addition, resulted of significance in predicting shorter TTFT. Significant variables for OS were: Binet stage, lymphadenopathy, splenomegaly, high LDH, high β2 microglobulin, 11q-, and CD38. In the multivariate analysis, only Binet stage, 11q-, and high β2microglobulin significantly predicted shorter OS. CLL with +12 entails a heterogeneous group with intermediate prognosis. However, a high proportion of cells carrying +12 separates a subgroup of patients with poor outcome. Copyright © 2015 John Wiley & Sons, Ltd.
authors.affiliation: Servicio de Hematología, Hospital Universitario Infanta Leonor, Madrid, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: González-Gascón Y Marín
authors.affiliation: Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Spain.|Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca (USAL-CSIC), Spain.
authors.forename: María
authors.initials: M
authors.lastname: Hernández-Sánchez
authors.affiliation: Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Spain.|Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca (USAL-CSIC), Spain.
authors.forename: Ana-Eugenia
authors.initials: AE
authors.lastname: Rodríguez-Vicente
authors.affiliation: Hospital Central de Asturias, Oviedo, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Sanzo
authors.affiliation: Hospital Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: Anna
authors.initials: A
authors.lastname: Aventín
authors.affiliation: Hospital del Mar, Barcelona, Spain.
authors.forename: Anna
authors.initials: A
authors.lastname: Puiggros
authors.affiliation: Hospital General, Valencia, Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Collado
authors.affiliation: Servicio de Hematología, Hospital Universitario Infanta Leonor, Madrid, Spain.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Heras
authors.affiliation: Servicio de Hematología, Hospital Universitario Infanta Leonor, Madrid, Spain.
authors.forename: Carolina
authors.initials: C
authors.lastname: Muñoz
authors.affiliation: Hospital Clinic i Provincial, Spain.
authors.forename: Julio
authors.initials: J
authors.lastname: Delgado
authors.affiliation: Hospital Vall d'Hebron, Barcelona, Spain.
authors.forename: Margarita
authors.initials: M
authors.lastname: Ortega
authors.affiliation: Fundación Pública Galega de Medicina Xenomica, Santiago de Compostela, Spain.
authors.forename: María-Teresa
authors.initials: MT
authors.lastname: González
authors.affiliation: Hospital Clínico Universitario, Valencia, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: Marugán
authors.affiliation: Hospital Rio Hortega, Valladolid, Spain.
authors.forename: Ignacio
authors.initials: I
authors.lastname: de la Fuente
authors.affiliation: Hospital Nuestra Señora de Sonsoles, Avila, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: Recio
authors.affiliation: Hospital Vall d'Hebron, Barcelona, Spain.
authors.forename: Francesc
authors.initials: F
authors.lastname: Bosch
authors.affiliation: Hospital del Mar, Barcelona, Spain.
authors.forename: Blanca
authors.initials: B
authors.lastname: Espinet
authors.affiliation: Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Spain.|Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca (USAL-CSIC), Spain.
authors.forename: Marcos
authors.initials: M
authors.lastname: González
authors.affiliation: Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Spain.|Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca (USAL-CSIC), Spain.
authors.forename: Jesús-María
authors.initials: JM
authors.lastname: Hernández-Rivas
authors.affiliation: Servicio de Hematología, Hospital Universitario Infanta Leonor, Madrid, Spain.|Universidad Complutense, Madrid, Spain.
authors.forename: José-Ángel
authors.initials: JÁ
authors.lastname: Hernández
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002881:Chromosomes, Human, Pair 12 / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000235:genetics* / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014314:Trisomy / Q000235:genetics*
keywords: +12; chronic lymphocytic leukemia; prognosis